Adverse effects and safety profile of perampanel: a review of pooled data.

@article{RUGGGUNN2014AdverseEA,
  title={Adverse effects and safety profile of perampanel: a review of pooled data.},
  author={FERGUS J. RUGG-GUNN},
  journal={Epilepsia},
  year={2014},
  volume={55 Suppl 1},
  pages={13-5}
}
Quality of life is directly related to the number and severity of adverse effects, and a successful antiepileptic medication must demonstrate a good balance between efficacy and tolerability. Perampanel is a newly licensed antiepileptic medication for the adjunctive treatment of patients (age 12 and older) with partial epilepsy with or without secondary generalization. Safety endpoints in the three phase III trials (304, 305, and 306) included treatment-emergent adverse events (TEAEs), vital… CONTINUE READING
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…